Cantor Fitzgerald reiterates Overweight on Celldex Therapeutics, $72 target
Cantor Fitzgerald maintained an Overweight rating on Celldex Therapeutics and set a $72.00 price target, implying 90.0% upside versus the Sep 21 close of $37.89.
Cantor Fitzgerald maintained an Overweight rating on Celldex Therapeutics and set a $72.00 price target, implying 90.0% upside versus the Sep 21 close of $37.89.